ClinicalTrials.gg
CompletedNCT02875366Updated Jun 17, 2019Results posted

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

A Phase 4 interventional study of LUM/IVA and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-06-17.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
10th of 20
70 · median 66
Started
2016
the only one that year
Phase 4
Only one
of the 20
Registered
15th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 10th largest by enrollment, is the only one that started in 2016, is the only one in phase 4, and was the 15th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the effect of LUM/IVA on exercise tolerance in subjects with CF, homozygous for the F508del-CFTR mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous for the F508del-CFTR mutation
  • Confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis
  • Stable CF disease as judged by the investigator
  • (FEV1) at least 40% and not greater than 90% of predicted

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that might confound the results of the study, interfere with the use of cardiopulmonary exercise tests (CPETs) as an assessment, or pose an additional risk in administering study drug to the subject
  • Any previous exposure to LUM or IVA
  • History of cardiac arrhythmia, ischemic heart disease, congestive heart failure, or other cardiac condition, or medical condition requiring chronic use of a beta blocker, non-dihydropyridine calcium channel blocker, or other cardiac medication known to affect exercise tolerance
  • History of solid organ or hematological transplantation
  • For subjects under 18 years of age at Screening, except those who have had bilateral lens removal, selected findings on a screening ophthalmologic examination will be exclusionary
  • Using or expected to require any concomitant medication that is prohibited in this study
  • History of alcohol or drug abuse, as deemed by the investigator, in the past year, including but not limited to cannabis, cocaine, and opiates
  • Participation in an drug study within 30 days before the Screening Visit
  • Pregnant or nursing females; males with a female partner who is pregnant or nursing
  • Colonization with organisms associated with a more rapid decline in pulmonary status
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.

    Drug: Placebo

  • Experimental
    LUM/IVA

    LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.

    Drug: LUM/IVA

Interventions

06

What researchers measure

Primary outcomes

  1. Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24

    CPET was used to assess change in exercise tolerance, as measured by VO2max.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Relative (Percent) Change From Baseline in Exercise Duration During CPET at Week 24

    Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.

    Time frame: Baseline, Week 24

  2. Absolute Change From Baseline in Exercise Duration During CPET at Week 24

    Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.

    Time frame: Baseline, Week 24

  3. Absolute Change From Baseline in VO2max During CPET at Week 24

    CPET was used to assess change in exercise tolerance, as measured by VO2max.

    Time frame: Baseline, Week 24

  4. Absolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 24

    Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.

    Time frame: Baseline, Week 24

  5. Relative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 24

    Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.

    Time frame: Baseline, Week 24

  6. Absolute Change From Baseline in Functional VO2 Gain at Week 24

    Time frame: Baseline, Week 24

  7. Relative (Percent) Change From Baseline in Functional VO2 Gain at Week 24

    Time frame: Baseline, Week 24

  8. Absolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24

    Time frame: Baseline, Week 24

  9. Relative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24

    Time frame: Baseline, Week 24

  10. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Week 24

  11. Relative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Week 24

  12. Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).

    Time frame: Baseline, Week 24

  13. Relative (Percent) Change From Baseline in BMI at Week 24

    BMI was defined as weight in kg divided by height in m\^2.

    Time frame: Baseline, Week 24

  14. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

    The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Week 24

  15. Number of Participants in Each Severity Category of Patient Health Questionnaire (PHQ-8)

    The PHQ-8 is an eight item self-reported measure of depression. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual eight items and ranges from 0 to 24, with higher scores indicating more severe depression symptoms. Total score of 0 to 5 indicates none to minimal depression, 6 to 10 indicates mild depression, 11 to 15 indicates moderate depression, 16 to 20 indicates moderately severe depression and 21 to 24 indicates severe depression.

    Time frame: Baseline, Week 24

  16. Number of Participants in Each Severity Category of Generalized Anxiety Disorder (GAD-7) Scores

    The GAD-7 is a seven item, self-reported measurement of GAD severity. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual seven items and ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms. Total score of 0 to 5 indicates none to minimal anxiety, 6 to 10 indicates mild anxiety, 11 to 15 indicates moderate anxiety, 16 to 21 indicates severe anxiety.

    Time frame: Baseline, Week 24

  17. Absolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activity counts.

    Time frame: Baseline, Week 24

  18. Relative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activities.

    Time frame: Baseline, Week 24

  19. Absolute Change From Baseline in Duration of Sleep Time at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.

    Time frame: Baseline, Week 24

  20. Relative (Percent) Change From Baseline in Duration of Sleep Time at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.

    Time frame: Baseline, Week 24

  21. Absolute Change From Baseline in Time Above Sedentary Duration at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.

    Time frame: Baseline, Week 24

  22. Relative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 24

    Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.

    Time frame: Baseline, Week 24

  23. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

07

Results

Posted Jun 17, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboLUM/IVA
Started3634
Completed3631
Not completed03
Withdrew: Adverse event02
Withdrew: Noncompliance01

Outcome measures

PrimaryRelative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24

CPET was used to assess change in exercise tolerance, as measured by VO2max.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24-3.5 (-7.7 to 0.8)-6.6 (-11.3 to -2.0)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.3021 · Least squares mean difference: -3.2 · 95% CI -9.2 to 2.9
SecondaryRelative (Percent) Change From Baseline in Exercise Duration During CPET at Week 24

Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in Exercise Duration During CPET at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Exercise Duration During CPET at Week 240.4 (-3.0 to 3.8)-2.8 (-6.5 to 1.0)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.1894 · Least squares mean difference: -3.2 · 95% CI -8.0 to 1.6
SecondaryAbsolute Change From Baseline in Exercise Duration During CPET at Week 24

Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · seconds
Absolute Change From Baseline in Exercise Duration During CPET at Week 24
secondsPlaceboLUM/IVA
Absolute Change From Baseline in Exercise Duration During CPET at Week 24-2.1 (-20.0 to 15.9)-17.4 (-37.2 to 2.4)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.2328 · Least squares mean difference: -15.3 · 95% CI -40.8 to 10.1
SecondaryAbsolute Change From Baseline in VO2max During CPET at Week 24

CPET was used to assess change in exercise tolerance, as measured by VO2max.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milliliter per kilogram per minute
Absolute Change From Baseline in VO2max During CPET at Week 24
milliliter per kilogram per minutePlaceboLUM/IVA
Absolute Change From Baseline in VO2max During CPET at Week 24-1.3 (-2.5 to -0.1)-2.7 (-4.0 to -1.3)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.1203 · Least squares mean difference: -1.4 · 95% CI -3.1 to 0.4
SecondaryAbsolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 24

Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milliliter per minute
Absolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 24
milliliter per minutePlaceboLUM/IVA
Absolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 2494.6 (-5.8 to 195.0)-55.1 (-168.0 to 57.9)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.0439 · Least squares mean difference: -149.6 · 95% CI -295.0 to -4.2
SecondaryRelative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 24

Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 249.4 (0.9 to 17.8)1.8 (-7.7 to 11.3)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.2237 · Least squares mean difference: -7.5 · 95% CI -19.8 to 4.7
SecondaryAbsolute Change From Baseline in Functional VO2 Gain at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milliliter per minute per watt
Absolute Change From Baseline in Functional VO2 Gain at Week 24
milliliter per minute per wattPlaceboLUM/IVA
Absolute Change From Baseline in Functional VO2 Gain at Week 240.07 (-0.29 to 0.43)-0.53 (-0.93 to -0.14)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.0226 · Least squares mean difference: -0.60 · 95% CI -1.12 to -0.09
SecondaryRelative (Percent) Change From Baseline in Functional VO2 Gain at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in Functional VO2 Gain at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Functional VO2 Gain at Week 241.46 (-3.10 to 6.03)-4.85 (-9.93 to 0.22)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.0613 · Least squares mean difference: -6.32 · 95% CI -12.94 to 0.31
SecondaryAbsolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · ratio
Absolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
ratioPlaceboLUM/IVA
Absolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 240.5 (-0.3 to 1.4)0.8 (-0.1 to 1.7)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.6409 · Least squares mean difference: 0.3 · 95% CI -0.9 to 1.5
SecondaryRelative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 242.0 (-0.7 to 4.6)3.0 (0.1 to 5.8)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.5889 · Least squares mean difference: 1.0 · 95% CI -2.7 to 4.7
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of predicted FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24
percentage of predicted FEV1PlaceboLUM/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24-4.0 (-7.3 to -0.7)-0.6 (-4.0 to 2.9)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.1460 · Least squares mean difference: 3.4 · 95% CI -1.2 to 8.1
SecondaryRelative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24-5.4 (-10.3 to -0.5)-1.8 (-6.9 to 3.2)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.3091 · Least squares mean difference: 3.5 · 95% CI -3.4 to 10.4
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg/m^2
Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
kg/m^2PlaceboLUM/IVA
Absolute Change From Baseline in Body Mass Index (BMI) at Week 240.3 (0.0 to 0.6)0.5 (0.1 to 0.8)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.3961 · Least squares mean difference: 0.2 · 95% CI -0.3 to 0.6
SecondaryRelative (Percent) Change From Baseline in BMI at Week 24

BMI was defined as weight in kg divided by height in m\^2.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percent change
Relative (Percent) Change From Baseline in BMI at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in BMI at Week 241.5 (0.0 to 3.1)2.5 (0.9 to 4.1)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.3905 · Least squares mean difference: 0.9 · 95% CI -1.2 to 3.1
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24
units on a scalePlaceboLUM/IVA
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24-6.1 (-11.7 to -0.5)0.1 (-5.9 to 6.1)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed effects model for repeated measure · p = 0.1257 · Least squares mean difference: 6.2 · 95% CI -1.8 to 14.1
SecondaryNumber of Participants in Each Severity Category of Patient Health Questionnaire (PHQ-8)

The PHQ-8 is an eight item self-reported measure of depression. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual eight items and ranges from 0 to 24, with higher scores indicating more severe depression symptoms. Total score of 0 to 5 indicates none to minimal depression, 6 to 10 indicates mild depression, 11 to 15 indicates moderate depression, 16 to 20 indicates moderately severe depression and 21 to 24 indicates severe depression.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants in Each Severity Category of Patient Health Questionnaire (PHQ-8)
participantsPlaceboLUM/IVA
Baseline: None to minimal2728
Baseline: Mild85
Baseline: Moderate01
Baseline: Moderately severe10
Baseline: Severe00
Week 24: None to minimal2324
Week 24: Mild83
Week 24: Moderate13
Week 24: Moderately severe10
Week 24: Severe00
SecondaryNumber of Participants in Each Severity Category of Generalized Anxiety Disorder (GAD-7) Scores

The GAD-7 is a seven item, self-reported measurement of GAD severity. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual seven items and ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms. Total score of 0 to 5 indicates none to minimal anxiety, 6 to 10 indicates mild anxiety, 11 to 15 indicates moderate anxiety, 16 to 21 indicates severe anxiety.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants in Each Severity Category of Generalized Anxiety Disorder (GAD-7) Scores
participantsPlaceboLUM/IVA
Baseline: None to minimal3129
Baseline: Mild55
Baseline: Moderate00
Baseline: Severe00
Week 24: None to minimal2626
Week 24: Mild63
Week 24: Moderate11
Week 24: Severe00
SecondaryAbsolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activity counts.

Time frame:
Baseline, Week 24
Reported as:
Mean · physical activity counts per day
Absolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24
physical activity counts per dayPlaceboLUM/IVA
Absolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24-23239 ± 73936.4-22409 ± 52450.1
SecondaryRelative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activities.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Relative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24-5 ± 26.9-7 ± 24.3
SecondaryAbsolute Change From Baseline in Duration of Sleep Time at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.

Time frame:
Baseline, Week 24
Reported as:
Mean · hours
Absolute Change From Baseline in Duration of Sleep Time at Week 24
hoursPlaceboLUM/IVA
Absolute Change From Baseline in Duration of Sleep Time at Week 24-0.4 ± 0.880.1 ± 0.74
SecondaryRelative (Percent) Change From Baseline in Duration of Sleep Time at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Relative (Percent) Change From Baseline in Duration of Sleep Time at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Duration of Sleep Time at Week 24-5.7 ± 12.301.5 ± 9.79
SecondaryAbsolute Change From Baseline in Time Above Sedentary Duration at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.

Time frame:
Baseline, Week 24
Reported as:
Mean · hours
Absolute Change From Baseline in Time Above Sedentary Duration at Week 24
hoursPlaceboLUM/IVA
Absolute Change From Baseline in Time Above Sedentary Duration at Week 24-0.7 ± 1.48-0.7 ± 2.09
SecondaryRelative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 24

Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Relative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 24
percent changePlaceboLUM/IVA
Relative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 240.2 ± 64.762.3 ± 77.18
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPlaceboLUM/IVA
Participants With AEs3530
Participants With SAEs915

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/36 (0%)9/36 (25%)34/36 (94.4%)
LUM/IVA0/34 (0%)15/34 (44.1%)28/34 (82.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboLUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations6/368/34
Distal intestinal obstruction syndromeGastrointestinal disorders0/362/34
Lower respiratory tract infection bacterialInfections and infestations0/361/34
Inguinal herniaGastrointestinal disorders0/361/34
TachycardiaCardiac disorders0/361/34
FatigueGeneral disorders0/361/34
Testicular torsionReproductive system and breast disorders0/361/34
DyspnoeaRespiratory, thoracic and mediastinal disorders0/361/34
InfectionInfections and infestations0/361/34
Cytomegalovirus infectionInfections and infestations1/360/34
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlaceboLUM/IVA
Respiration abnormalRespiratory, thoracic and mediastinal disorders9/365/34
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations6/368/34
CoughRespiratory, thoracic and mediastinal disorders8/365/34
Sputum increasedRespiratory, thoracic and mediastinal disorders5/362/34
NauseaGastrointestinal disorders5/363/34
Upper respiratory tract infectionInfections and infestations4/364/34
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/361/34
NasopharyngitisInfections and infestations3/363/34
HaemoptysisRespiratory, thoracic and mediastinal disorders1/363/34
Increased viscosity of bronchial secretionRespiratory, thoracic and mediastinal disorders0/363/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLUM/IVATotal
Mean26.1 ± 10.5824.9 ± 10.1725.5 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLUM/IVATotal
Female181331
Male182139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLUM/IVATotal
Hispanic or Latino000
Not Hispanic or Latino363470
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLUM/IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White363470
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Melbourne, Victoria, Australia
  • Parkville, Victoria, Australia
  • Adelaide, Australia
  • Camperdown, Australia
  • Clayton, Australia
  • Nedlands, Australia
  • New Lambton Heights, Australia
  • Randwick, Australia
  • South Brisbane, Australia
  • Subiaco, Australia
  • Westmead, Australia
  • Edinburgh, United Kingdom
09

References and documents

Publications

  • Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, Tian S, Harris RA, Kotsimbos T, Keating D. VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. J Cyst Fibros. 2021 May;20(3):499-505. doi: 10.1016/j.jcf.2020.12.006. Epub 2020 Dec 24. PubMed 33358691 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Sep 2017, 12 months.

Results were first posted in Jun 2019, 1 year 9 months after primary completion.

Of 30 phase 4 interventional studies under Cystic Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2016
First posted
Aug 23, 2016
StartActual
Sep 2016
Primary completionActual
Sep 2017
CompletionActual
Oct 2017
Results first posted
Jun 17, 2019
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02875366
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Sep 2016
Primary completion
Sep 2017
Completion
Oct 2017
Results posted
Jun 17, 2019
Last update
Jun 17, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion